Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Lenvatinib versus Sorafenib in First-Line Treatment of Older Patients with Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial.
Journal: Liver cancer
Published: December 23, 2025
Characterization of Patients with Unresectable Hepatocellular Carcinoma in REFLECT Who Achieved Tumor Response or Alpha-Fetoprotein Response When Treated with Lenvatinib.
Journal: Liver cancer
Published: October 24, 2025
Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Journal: JCO precision oncology
Published: October 16, 2025
Characterization and Management of Adverse Reactions in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib.
Journal: Journal of the advanced practitioner in oncology
Published: January 10, 2024
A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116.
Journal: Liver cancer
Published: May 19, 2023
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.
Journal: JCO precision oncology
Published: April 20, 2023
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.
Journal: JAMA oncology
Published: December 08, 2022
Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 22, 2021
Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress.
Journal: Cancers
Published: May 27, 2021
Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma.
Journal: Liver cancer
Published: December 11, 2020
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 13, 2020
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 28, 2020
Last Updated: 09/26/2026